{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:17:04Z","timestamp":1791026224940,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T00:00:00Z","timestamp":1352764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00223-012-9668-4","type":"journal-article","created":{"date-parts":[[2012,11,12]],"date-time":"2012-11-12T06:27:02Z","timestamp":1352701622000},"page":"59-67","source":"Crossref","is-referenced-by-count":10,"title":["A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data"],"prefix":"10.1007","volume":"92","author":[{"given":"Michael R.","family":"McClung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude-Laurent","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulema","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Tlustochowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Eusebio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Balske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Matzkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech P.","family":"Olszynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Recker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D.","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,13]]},"reference":[{"key":"9668_CR1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","volume":"21","author":"R Emkey","year":"2005","unstructured":"Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895\u20131903","journal-title":"Curr Med Res Opin"},{"key":"9668_CR2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","volume":"80","author":"RR Recker","year":"2005","unstructured":"Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856\u2013861","journal-title":"Mayo Clin Proc"},{"key":"9668_CR3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","volume":"60","author":"A Cooper","year":"2006","unstructured":"Cooper A, Drake J, Brankin E, PERSIST Investigators (2006) Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896\u2013905","journal-title":"Int J Clin Pract"},{"key":"9668_CR4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, Vertebral efficacy with risedronate therapy (VERT) study group (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"9668_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, Vertebral efficacy with risedronate therapy (VERT) study group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"9668_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip intervention program study group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"9668_CR7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103\u2013111","journal-title":"Calcif Tissue Int"},{"key":"9668_CR8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00198-007-0531-9","volume":"19","author":"PD Delmas","year":"2008","unstructured":"Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR, McClung MR (2008) Monthly dosing of 75\u00a0mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 19:1039\u20131045","journal-title":"Osteoporos Int"},{"key":"9668_CR9","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20134387","journal-title":"J Clin Endocrinol Metab"},{"key":"9668_CR10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1185\/030079904125003566","volume":"20","author":"ST Harris","year":"2004","unstructured":"Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP (2004) Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 20:757\u2013764","journal-title":"Curr Med Res Opin"},{"key":"9668_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","volume":"42","author":"PD Delmas","year":"2008","unstructured":"Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S (2008) Efficacy and safety of risedronate 150\u00a0mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36\u201342","journal-title":"Bone"},{"key":"9668_CR12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105\u20132115","journal-title":"J Bone Miner Res"},{"key":"9668_CR13","first-page":"712","volume":"357","author":"R Karam","year":"2007","unstructured":"Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712\u2013713","journal-title":"N Engl J Med"},{"key":"9668_CR14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"NB Watts","year":"2008","unstructured":"Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365\u2013372","journal-title":"Osteoporos Int"},{"key":"9668_CR15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"9668_CR16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"DD Mellstr\u00f6m","year":"2004","unstructured":"Mellstr\u00f6m DD, S\u00f6rensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462\u2013468","journal-title":"Calcif Tissue Int"},{"issue":"suppl 1","key":"9668_CR17","first-page":"S162","volume":"78","author":"GA Thompson","year":"2006","unstructured":"Thompson GA, Russell DA, Schnell DJ, Burgio DE, Sun LA (2006) Risedronate pharmacokinetics following daily and monthly dosing regimes. Calcif Tissue Int 78(suppl 1):S162","journal-title":"Calcif Tissue Int"},{"key":"9668_CR18","doi-asserted-by":"crossref","unstructured":"McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P (2012) Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int [Epub ahead of print]","DOI":"10.1007\/s00198-012-2056-0"},{"key":"9668_CR19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jocd.2009.09.005","volume":"13","author":"NB Watts","year":"2010","unstructured":"Watts NB, Brown JP, Cline G (2010) Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1\u00a0year compared with historical placebo. J Clin Densitom 13:56\u201362","journal-title":"J Clin Densitom"},{"key":"9668_CR20","unstructured":"EMEA Committee for Medicinal Products for Human Use (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. http:\/\/www.emea.europa.eu\/pdfs\/human\/ewp\/55295enfin.pdf . Accessed Jan 2010"},{"key":"9668_CR21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1185\/030079906X154042","volume":"22","author":"DT Gold","year":"2006","unstructured":"Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383\u20132391","journal-title":"Curr Med Res Opin"},{"key":"9668_CR22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1185\/030079906X154079","volume":"22","author":"R Keen","year":"2006","unstructured":"Keen R, Jodar E, Iolascon G, Kruse HP, Varbanov A, Mann B, Gold DT (2006) European women\u2019s preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 22:2375\u20132381","journal-title":"Curr Med Res Opin"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-012-9668-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-012-9668-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-012-9668-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T14:09:48Z","timestamp":1562335788000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-012-9668-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,13]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["9668"],"URL":"https:\/\/doi.org\/10.1007\/s00223-012-9668-4","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,13]]}}}